FDA Approves Esketamine for Treatment-Resistant Depression, While US Suicide Rate Reaches Record High
The US FDA approved esketamine nasal spray on March 5th, 2019, while deaths from synthetic opioids and suicides hit a record high in 2017.
Esketamine for treatment-resistant depression submitted to FDA
/1 Comment/in Depression, Psychopharmacology /by Gerhard GründerJanssen Pharmaceuticals announced that the company on September 4th, 2018, submitted a New Drug Application to the US FDA for esketamine nasal spray for treatment-resistant depression.
A Lecture on the “Crisis in Psychopharmacology”
/0 Comments/in Education, Psychopharmacology, Video /by Gerhard GründerLecture on “The Crisis of Psychopharmacology” at the scientific colloquium of the Department of Psychiatry and Psychotherapy of the University of Rostock.
DGPPN Summer School “Psychopharmacology” 2018 in Berlin
/0 Comments/in Education, Psychopharmacology /by Gerhard GründerOn June 28 and 29, 2018, the Summer School “Psychopharmacology”, organized by the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neuroscience (DGPPN), will be held in Berlin.
“Langzeittherapie mit Psychopharmaka” bei Frag-den-Professor
/0 Comments/in Education, Psychopharmacology, Teaching /by Gerhard GründerMy presentation on “long-term treatment with psychotropic drugs” (“Langzeittherapie mit Psychopharmaka”) on the web platform “Frag-den-Professor”.
How effective are antidepressants?
/1 Comment/in Antidepressants, Metaanalysis, Psychopharmacology /by Gerhard GründerAndrea Cipriani from the University of Oxford and colleagues have recently published the largest and most comprehensive meta-analysis of the efficacy of antidepressants in the Lancet. The paper is worth dealing with more intensively.
A lecture on polypharmacy and pharmacokinetics
/0 Comments/in Pharmacokinetics, Polypharmacy, Psychopharmacology /by Gerhard GründerA video of my lecture on “Polypharmacy and Pharmacokinetics”, which I gave at the “Psychiatrie-Akademie” in Brugg, Switzerland on January 11th, 2018. This talk was given in German.
Join me me at the Central Institute of Mental Health
/0 Comments/in Gerhard Gründer, Psychiatry, Psychopharmacology, Teaching /by Gerhard GründerWork with me at the Central Institute of Mental Health (CIMH) in Mannheim and build with me the future of psychiatry.
“The new paths of psychiatry” in WDR
/0 Comments/in Broadcast, Psychiatry, Psychopharmacology /by Gerhard GründerThe Westdeutscher Rundfunk (WDR) on October 8th and 9th, 2017, broadcasted an interesting feature on the “new paths of psychiatry”, which contains many statements I made during an interview on the future of psychopharmacology.
Cariprazine: the next touchstone for the German AMNOG
/0 Comments/in Antipsychotics, Psychopharmacology /by Gerhard GründerThe interesting new antipsychotic compound cariprazine was recently approved by the European Medicines Agency (EMA). Its launch in Germany will be a new touchstone for the German Act on the Reform of the Market for Medicinal Products (AMNOG).